DM
KZR

Deerfield Management’s Kezar Life Sciences KZR Stock Holding History

Deerfield Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-143,000
Closed -$10.1M – 109
2022
Q4 		$10.1M Buy
+143,000
New +$10.6M 0.21% 72
2022
Q3 		– Sell
-141,900
Closed -$11.7M – 131
2022
Q2 		$11.7M Buy
+141,900
New +$12.5M 0.24% 73

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Deerfield Management's KZR Position: Q1 2023 in Review

Deerfield Management sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 143,000 shares — an estimated $10.1M sold.

Deerfield Management first reported a position in KZR in Q2 2022 and held it in 2 quarters. The position peaked at $11.7M in Q2 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Deerfield Management reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Deerfield Management sold 143,000 Kezar Life Sciences shares in Q1 2023, an estimated $10.1M.
  • Deerfield Management first reported a position in Kezar Life Sciences in Q2 2022 and held it in 2 quarters.
  • Deerfield Management's Kezar Life Sciences position peaked at $11.7M in Q2 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Deerfield Management's 13F filing for Q1 2023, filed 15 May 2023.